JDS Therapeutics, LLC Welcomes Gregg Bresner as Chief Financial Officer

PURCHASE, NY, April 11, 2012 – JDS Therapeutics, LLC, a marketer of proprietary, high-quality healthcare products to physicians, healthcare-delivery networks, and other healthcare professionals, announced today that Gregg Bresner, CFA, has joined JDS Therapeutics as Chief Financial Officer.  Mr. Bresner will be responsible for overseeing the financial, accounting, and human resources departments at JDS Therapeutics.

Mr. Bresner has 21 years of experience as a financial professional, with a focus on corporate development, corporate financings and asset management. Prior to joining JDS Therapeutics, Mr. Bresner was Managing Partner and Chief Financial Officer of Tyto Capital Partners, an investment firm focused on private debt and equity investments. Mr. Bresner had previously co-founded Briscoe Capital Management, an SEC registered firm that managed approximately $400 million in corporate loan and debt assets. Mr. Bresner was a Portfolio Manager and Chief Financial Officer for the Briscoe platform, where he led the firm’s investments in the healthcare and specialty pharmaceutical sectors. Briscoe Capital merged into a larger, multi-strategy investment manager in 2006. Prior to co-founding Briscoe Capital, Mr. Bresner held investment banking positions with firms including Deutsche Bank, Bankers Trust Company and Wasserstein Perella & Company, where he focused on mergers & acquisitions and corporate finance. Mr. Bresner began his career as a management consultant with Coopers & Lybrand. Mr. Bresner has served on a variety of privately-held corporate and public-sector boards.

Mr. Bresner holds a B.S. from Rensselaer Polytechnic Institute and an M.B.A. from the Columbia University Graduate School of Business.

Commenting on the announcement, Michael Satow, President and CEO of JDS Therapeutics LLC, stated, “We are extremely pleased to announce that Gregg Bresner has joined JDS Therapeutics as Chief Financial Officer. We are confident that Gregg’s financial expertise will be invaluable to JDS as we begin to commercialize our portfolio and enter a period of sustained and profitable growth.  Gregg’s business and financial experience are perfectly suited to our financial and accounting needs.”

About JDS Therapeutics:
JDS Therapeutics markets proprietary, high-quality healthcare products to physicians, healthcare-delivery networks, and other healthcare professionals. JDS is focused on providing patients with scientifically backed, natural approaches to meeting their healthcare needs. JDS Therapeutics owns more than 100 issued patents worldwide involving clinically active natural compounds. JDS was founded in 2011, by Phillip and Michael Satow, a father and son team whose previous company, JDS Pharmaceuticals was sold in 2007 to Noven Pharmaceuticals for $125 million.

For more information, please contact us.